Status:
RECRUITING
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC
Lead Sponsor:
University Hospital, Lille
Conditions:
Hepatocellular Carcinoma
Liver Transplant
Eligibility:
All Genders
18+ years
Brief Summary
HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation i...
Eligibility Criteria
Inclusion
- Patient candidate for liver transplantation for hepatocellular carcinoma from the University Hospital of Lille and Rouen, whose therapeutic transplantation project has been validated and having an AFP score ≤ 2 (diagnosis of HCC defined on non-invasive imaging criteria according to the recommendations of EASL-EORTC 2012 or confirmed histologically).
- No opposition to participating in the study.
- Patient affiliated to a social security scheme
Exclusion
- Patient with an AFP score ≥ 3
- Patient contraindicated to PET FDG or Choline.
- Other tumor: Cholangiocarcinoma.
- Diabetes unbalanced HbA1c\> 9%, and fasting hyperglycemia (\> 2g / L) which does not allow the completion of the PET examination.
- Patient under guardianship or curatorship.
- Pregnant or breastfeeding woman.
Key Trial Info
Start Date :
June 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04792801
Start Date
June 22 2021
End Date
June 1 2028
Last Update
March 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hop Claude Huriez Chu Lille
Lille, France, 59037